There is no effective treatment method for nonalcoholic fatty liver disease (NAFLD), the most common liver disease. The exact mechanism underlying the pathogenesis of NAFLD remains to be elucidated. Here, we report that tumor necrosis factor receptor-associated ubiquitous scaffolding and signaling protein (TRUSS) acts as a positive regulator of NAFLD and in a variety of metabolic disorders. TRUSS expression was increased in the human liver specimens with NAFLD or nonalcoholic steatohepatitis, and in the livers of high-fat diet (HFD)-induced and genetically obese mice. Conditional knockout of TRUSS in hepatocytes significantly ameliorated hepatic steatosis, insulin resistance, glucose intolerance, and inflammatory responses in mice after HFD challenge or in spontaneous obese mice with normal chow feeding. All of these HFDinduced pathological phenotypes were exacerbated in mice overexpressing TRUSS in hepatocytes. We show that TRUSS physically interacts with the inhibitor of nuclear factor κB α (IκBα) and promotes the ubiquitination and degradation of IκBα, which leads to aberrant activation of nuclear factor κB (NF-κB). Overexpressing IκBα S32A/S36A , a phosphorylation- N onalcoholic fatty liver disease (NAFLD) is the most common type of chronic liver disease and is histologically characterized by excessive fat accumulation in the liver.
TRUSS Exacerbates NAFLD Development by Promoting IκBα Degradation in Mice
There is no effective treatment method for nonalcoholic fatty liver disease (NAFLD), the most common liver disease. The exact mechanism underlying the pathogenesis of NAFLD remains to be elucidated. Here, we report that tumor necrosis factor receptor-associated ubiquitous scaffolding and signaling protein (TRUSS) acts as a positive regulator of NAFLD and in a variety of metabolic disorders. TRUSS expression was increased in the human liver specimens with NAFLD or nonalcoholic steatohepatitis, and in the livers of high-fat diet (HFD)-induced and genetically obese mice. Conditional knockout of TRUSS in hepatocytes significantly ameliorated hepatic steatosis, insulin resistance, glucose intolerance, and inflammatory responses in mice after HFD challenge or in spontaneous obese mice with normal chow feeding. All of these HFDinduced pathological phenotypes were exacerbated in mice overexpressing TRUSS in hepatocytes. We show that TRUSS physically interacts with the inhibitor of nuclear factor κB α (IκBα) and promotes the ubiquitination and degradation of IκBα, which leads to aberrant activation of nuclear factor κB (NF-κB). Overexpressing IκBα S32A/S36A , a phosphorylation- N onalcoholic fatty liver disease (NAFLD) is the most common type of chronic liver disease and is histologically characterized by excessive fat accumulation in the liver. (1, 2) Accumulative evidence has revealed that inflammation plays a key role in the initiation, propagation, and development of NAFLD. (3) (4) (5) Overt inflammation and liver injury promotes progression from simple steatosis to nonalcoholic steatohepatitis (NASH), a causal factor for cirrhosis and hepatocellular carcinoma. (6) The worldwide prevalence of NAFLD in the general population is estimated to be 5 to 30%, and the incidence is higher in patients with components of metabolic disorders such as obesity, hyperlipidemia, and diabetes. (7, 8) Moreover, patients with NAFLD have a significantly higher risk of developing cardiovascular diseases. (9) Thus, controlling the development of NAFLD not only benefits liver disease prevention but also extensively mitigates cardiometabolic diseases. Unfortunately, there is no effective pharmacological treatment available in the clinic, even though weight loss by dietary modification and exercise has beneficial effects on liver fat accumulation. (10, 11) In this study, we identified a key player, tumor necrosis factor receptor-associated ubiquitous scaffolding and signaling protein (TRUSS), in the pathological processes of NAFLD. TRUSS (encoded by TRUSS, also known as TRPC4AP) was characterized as a tumor necrosis factor receptor 1 (TNF-R1)-interacting protein with a mass of approximately 91 kDa. (12) The TRUSS mRNA is widely expressed in mouse tissues but enriched in the brain, heart, liver, and testis. Functional studies indicated that TRUSS is capable of activating a number of transcription factors, including nuclear factor κB (NF-κB) and activator protein 1, and can serve as a scaffolding protein that links TNF-R1 to its downstream components. (12, 13) Additionally, TRUSS works synergistically with transient receptor potential canonical (TRPC) ion channels to augment Ca 2+ entry in the context of m1 muscarinic acetylcholine receptor (m1AchR) signaling activation. (14) Several studies have suggested that TRUSS might play a role in the pathological process of several diseases. (15) (16) (17) For instance, single nucleotide polymorphisms in TRUSS might be a risk factor for Alzheimer's disease. (15, 16) However, the potential role of TRUSS in the development of NAFLD remains unexploited.
In this study, we identified that TRUSS plays a pivotal role in the development of NAFLD. We used gain-of-function and loss-of-function approaches to demonstrate that TRUSS exacerbates HFD-induced and genetic deficiency-induced hepatic steatosis, insulin resistance (IR), abnormal glucose metabolism, and inflammatory response. We further explored the potential mechanisms by which TRUSS promotes NAFLD.
Materials and Methods

aNIMalS aND tReatMeNt
All animal procedures were approved by the Animal Care and Use Committee of both Harbin Medical University Cancer Hospital and Renmin Hospital of Wuhan University and were conducted in accordance with the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health.
TRUSS flox/flox (TRUSS-Flox) mice (C57BL/6J background) were constructed using the CRISPR/ Cas9 technique. (18, 19) Then, hepatocyte-specific TRUSS knockout (TRUSS-HKO) mice were generated by mating TRUSS-Flox mice with albumin-Cre mice. The conditional TRUSS transgenic mice were generated by microinjection of the CAG-LoxP-CAT-LoxP-TRUSS cassette into fertilized C57BL/6J mouse embryos. Then, TRUSS hepatocyte-specific transgenic mice (TRUSS-HTG) were generated by crossing the obtained mice with albumin-Cre mice. The leptin-deficient heterozygous (ob/+) mice were crossed with TRUSS-HKO mice to delete the expression of TRUSS in the hepatocytes of leptin-deficient homozygous (ob/ob) mice (hereafter referred to as ob/ ob-HKO). The albumin-IκBα S32A/S36A mice were generated and crossed with TRUSS-HTG mice togenerate hepatocyte-specific TRUSS and IκBα S32A/S36A double transgenic (DTG) mice.
All animal experiments were performed using male mice aged 8 to 10 weeks, and mice were housed in a temperature-controlled environment (23 ± 2°C) with a 
HuMaN SaMpleS
All procedures involving human samples were approved by the Renmin Hospital of Wuhan University Review Board and conducted in accordance with the Declaration of Helsinki. Control samples were obtained from living donors who underwent liver resections due to liver hemangiomas or hepatic cysts. Steatosis samples were collected from NAFLD or NASH patients undergoing liver biopsy, resection, or transplantation. Exclusion criteria were as follows: consumption of more than 140 g/week of alcohol for men and more than 70 g/ week of alcohol for women at the time of the analysis or in the previous 6 months; presence of hepatitis B surface antigen or antihepatitis C virus antibodies; and use of toxins or drugs. Written informed consent was obtained from each subject or from the family of the liver donor.
MeaSuReMeNtS oF MetaBolIC INDICeS aND SeRuM CytoKINe aNalySeS
Fasting blood glucose levels, fasting serum insulin levels, and homeostatic model assessment of insulin resistance (HOMA-IR) values, triglyceride (TG) levels, total cholesterol (TC) levels, nonesterified fatty acid (NEFA) levels, and the serum cytokines levels including interleukin (IL)-1β, IL-6, and TNFα were tested as previously described. (4, 5, 20) 
gluCoSe aND INSulIN toleRaNCe teStINg
For the glucose tolerance tests (GTT) and insulin tolerance tests (ITT), mice were fasted overnight prior to intraperitoneal injection of 1 g/kg body weight (BW) glucose (Sigma, St. Louis, MO) or 0.75 U/kg BW insulin (Novolin R, Novo Nordisk, Bagsvaerd, Denmark). Blood glucose levels were detected from the tail at baseline and 15, 30, 60, and 120 minutes after injection. (4, 5, 20) 
lIVeR FuNCtIoN
The alanine amino transferase (ALT) and aspartate amino transferase (AST) levels were measured in the serum with an ADVIA 2400 Chemistry System analyzer (Siemens, Tarrytown, NY), according to the manufacturer's instructions.
pRIMaRy HepatoCyte ISolatIoN aND ReCoMBINaNt aDeNoVIRuS INFeCtIoN
Primary hepatocytes from 6-week-old to 8-weekold male mice were isolated using a two-step collagenase perfusion method. (5, 20) Palmitate (PA, 0.25 mmol/L; Sigma) was applied to establish an in vitro model for the study of NAFLD. For viral infection experiments, serum-starved cells were infected with adenoviruses carrying mouse TRUSS complementary DNA (cDNA) (AdTRUSS) and a short hairpin RNA (shRNA) targeting TRUSS (AdshTRUSS) to overexpress or knock down TRUSS, respectively. Similar adenoviral vectors encoding the green fluorescent protein gene or scrambled shRNA were used as controls.
plaSMID pRoDuCtIoN
The following plasmids were constructed by PCR and used in different experiments of this study: hemagglutinin (HA)-TRUSS, octapeptide epitope tag (FLAG)-IκBα, FLAG-IκBα S32A/S36A
, glutathione-S-transferase (GST)-IκBα, His-TRUSS, GST-TRUSS, His-IκBα, Hisubiquitin (His-Ub), HA-IκBα, FLAG-TRUSS (1-400 aa), FLAG-TRUSS (401-600 aa), and FLAG-TRUSS (601-797 aa). The mammalian two-hybrid system, including plasmids pM, pVP16, Gal4-dependent luciferase reporter (Gal4-Luc), pM-IKKα (inhibitor of nuclear factor kappa B kinase), pM-IKKβ, pM-IKKγ, pVP16-IKKα, pVP16-IKKβ and pVP16-IKKγ, were kind gifts from Prof. Zan Huang (Wuhan University, China).
IMMuNopReCIpItatIoN
Immunoprecipitation (IP) assays were performed to examine the interactions between TRUSS and IκBα and the binding region of TRUSS with IκBα. (5, 21) luCIFeRaSe RepoRteR aSSay Luciferase assays were performed in HEK293T cells. In brief, HEK293T cells were co-transfected with Gal4-luc and combination of HA-TRUSS or control, and the indicated bait and prey plasmids. The Renilla luciferase was served as internal control. Luciferase activity was measured as previously described. (21) 
IN VIVO uBIQuItINatIoN aSSay
The in vivo ubiquitination assay was performed to detect the effect of TRUSS on the ubiquitination of IκBα as previously described. (20) 
HIStologICal aNalySeS aND IMMuNoHIStoCHeMIStRy
Hematoxylin and eosin (H&E) and Oil Red O (ORO) staining were performed on paraffinembedded and frozen liver sections, respectively. (20) (21) (22) Immunohistochemistry staining was performed to detect the expression of TRUSS in human liver sections. 
Real-tIMe pCR
Real-time PCR was performed as previously described. (21, 22) Briefly, after total RNA isolation and cDNA synthesis, real-time PCR was conducted with the LightCycler 480 QPCR System (Roche). The relative quantity of the targeted RNA was calculated through normalization to the quantity of the corresponding β-actin mRNA level.
WeSteRN Blot
Western blot analysis was performed as previously described. (21, 22) Total protein was extracted from the liver tissues and cultured cells with lysis buffer. Then, the protein samples were separated by gel electrophoresis and transferred to a polyvinylidene fluoride membrane. Protein expression was detected using the corresponding antibodies.
StatIStICal aNalySIS
The data were presented as the mean ± SD. All statistical analyses were performed with the SPSS software (version 20.0; IBM Corp, Armonk, NY). The normal distribution was tested for all data sets using the Shapiro-Wilkinson normality test. For normally distributed data, comparisons between two groups were performed using the unpaired Student t test, and differences between groups were calculated for significance using a one-way analysis of variance, followed by the Bonferroni post hoc test or Tamhane's T2 post hoc test.
For abnormally distributed data, the Mann-Whitney U test or Kruskal-Wallis test was applied to determine significance. A value of P < 0.05 was considered to indicate statistically significant difference.
aDDItIoNal MetHoDS
Additional methods and detailed descriptions are provided in the online supporting information.
Results
tRuSS eXpReSSIoN IS INCReaSeD IN Fatty lIVeRS
To characterize the involvement of TRUSS in the pathogenesis of NAFLD, the expression levels of TRUSS were examined in the livers of human subjects with NAFLD and NASH. Protein expression of TRUSS was significantly upregulated in the human samples with NAFLD and NASH, compared with that in the nonsteatosis controls (Fig. 1A,B) . Furthermore, the expression profile of TRUSS was examined in the liver, fat, and muscle from HFD-induced and leptin-deficient (ob/ob) obese mouse models. Compared with the mice fed with NC diet, TRUSS expression was significantly increased in the livers of mice fed with HFD for 12 weeks (Fig. 1C ), albeit the HFD had no effect on the expression levels of TRUSS in fat or muscle tissues (Supporting Fig. S1A ). Furthermore, 12 weeks after feeding the mice with NC diet, TRUSS expression was significantly elevated in the livers of ob/ob mice, without affecting the expression levels of TRUSS in fat or muscle tissues ( Fig. 1D and Supporting Fig. S1B ). Treatment of primary cultured mouse hepatocytes with PA also upregulated expression of TRUSS (Fig. 1E) . However, the expression levels of TRUSS mRNA were not altered in human liver samples with NAFLD and in the liver samples of mice fed with HFD, as compared with their respective controls (Supporting Fig. S1C,S1D ). Taken together, our data suggest that TRUSS may play a role in pathological stimuli-induced development and progression of NAFLD.
loSS oF tRuSS IN HepatoCyteS MItIgateS HFD-INDuCeD HepatIC SteatoSIS aND tHe INFlaMMatoRy ReSpoNSe
To investigate the tissue-specific role of TRUSS in the pathogenesis of NAFLD and related metabolic disorders, we generated a hepatocyte-specific TRUSS knockout (hereafter referred to as TRUSS-HKO) mice (Supporting Fig. S2A-S2C ). TRUSS flox/flox (TRUSSFlox) mice served as the controls. HFD administration caused a significant elevation in the BW of both genotypes compared with the age-matched and gender-matched mice that were fed the NC diet ( Fig. 2A) . Regardless of the diet, BWs of TRUSS-HKO mice were similar to their control counterparts ( Fig. 2A) . Conversely, the liver weights (LWs) from the HFDfed TRUSS-HKO mice were significantly lower than the LWs of the TRUSS-Flox mice, as evaluated by the LW and LW/BW ratios (Fig. 2B,2C) . Additionally, the TRUSS-HKO mice showed decreased levels of serum ALT and AST, two markers of liver damage, suggesting an improved liver function in TRUSS-HKO mice (Fig. 2D) . The results of the H&E and ORO staining analysis demonstrated that there was an obvious diminished lipid accumulation in the livers of the HFD-fed TRUSS-HKO mice compared with the HFD-fed controls (Fig. 2E) , suggesting that the TRUSS-HKO genotype protected against HFD-induced hepatic steatosis in mice. Consistently, the HFD-induced elevation in the liver and serum lipid levels (including TG, TC, and NEFA) seen in the TRUSS-Flox mice were also significantly reduced in the TRUSS-HKO mice (Fig. 2F,2G) . Furthermore, TRUSS-HKO significantly attenuated the mRNA levels of genes involved in fatty acid synthesis (SREBP-1c, FAS, and ACCα) but significantly enhanced the expression of genes related to fatty acid β-oxidation (CPT-1α, PPARα, and ACOX-1) (Fig. 2H) . Consistently, knockdown of the TRUSS gene through infection with a recombinant adenoviral vector expressing a TRUSS-specific short hairpin RNA (AdshTRUSS) significantly reduced PA-induced lipid accumulation in primary cultured mouse hepatocytes (Supporting Fig. S2D,S2E) .
NAFLD is associated with chronic low-grade inflammation, which contributes to the development of hepatic steatosis, IR, and other metabolic disorders. We further examined the circulating and hepatic expression levels of cytokines or chemokines in TRUSS-HKO mice and their littermate controls to determine whether TRUSS contributes to overnutrition-induced inflammation. The TRUSS-HKO mice had lower serum concentrations of inflammatory mediators including IL-1β, IL-6, and TNFα than the TRUSS-Flox mice after 12 weeks of the HFD (Fig. 2I) . Moreover, the gene expression levels of IL-1β, IL-6, TNFα, and MCP1 in the liver were also significantly decreased in the TRUSS-HKO mice (Fig. 2J) . Conversely, much higher levels of anti-inflammatory factor IL-10 were seen in the TRUSS-HKO mice (Fig. 2J) . Collectively, these data strongly suggest that loss of TRUSS in hepatocytes protects mice from HFD-induced hepatic steatosis, liver injury, and local and systemic inflammatory responses.
loSS oF tRuSS IN HepatoCyteS atteNuateS HFD-INDuCeD IR aND aBNoRMal gluCoSe MetaBolISM
Because IR and hyperglycemia are frequently associated with obesity and NAFLD progression, we examined whether systemic insulin sensitivity and glucose metabolism were affected by hepatocyte-specific TRUSS deletion. We found that the fasted blood glucose levels, fasted serum insulin levels, and HOMA-IR of the TRUSS-HKO mice and TRUSS-Flox mice were comparable on the NC diet (Fig. 3A-3C ). Importantly, HFD-induced hyperglycemia and hyperinsulinemia were significantly attenuated by TRUSS-HKO (Fig. 3A-3C ). Moreover, HFD-induced impairment in glucose tolerance and insulin sensitivity were significantly improved by TRUSS-HKO (Fig. 3D,3E) . Additionally, the mRNA and relative protein levels of the gluconeogenesis-related enzymes, namely, phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase), were significantly decreased in the HFD-fed TRUSS-HKO mice (Fig. 3F,3G) . Furthermore, the insulin-induced phosphorylation levels of insulin receptor substrate 1 (IRS1), protein kinase B (AKT), and glycogen synthase kinase 3β (GSK3β) were increased in the livers of the HFDfed TRUSS-HKO mice after insulin administration (Fig. 3H) . These results suggest that TRUSS ablation in hepatocytes improved HFD-induced systemic and hepatic IR and impaired glucose homeostasis.
HepatoCyte-SpeCIFIC tRuSS oVeReXpReSSIoN pRoMoteS HFD-INDuCeD HepatIC SteatoSIS, INFlaMMatIoN, aND MetaBolIC DISoRDeRS
We next generated hepatocyte-specific TRUSS transgenic (TRUSS-HTG) mice to further explore its role in the progression of NAFLD and related metabolic disorders (Supporting Fig. S3A,S3B) . Hereafter, the relative control mice that did not express exogenous TRUSS were referred to as wild-type (WT) mice. The TRUSS-HTG mice developed similar extents of obesity with the WT mice after 12 weeks of the HFD; however, LW and LW/BW ratios were significantly higher in TRUSS-HTG mice than in WT mice ( Fig. 4A-4C ). Moreover, TRUSS-HTG promoted HFD-induced chronic hepatic injury, production and accumulation of lipids both in the liver and serum, and inflammatory response as reflected by their respective indices (Fig. 4D-4J ). The PA-induced lipid accumulation was further increased by adenovirus-mediated overexpression of TRUSS in primary cultured hepatocytes (Supporting Fig. S3C,S3D) . Opposite to what was observed in TRUSS-HKO mice, the HFDinduced abnormal glucose metabolism and IR were significantly exacerbated in the TRUSS-HTG mice (Fig. 5A-5G) . Consistently, the sensitivity of the insulin signaling cascades in response to the insulin injection decreased in the TRUSS-HTG mice, as indicated by the decreased phosphorylation levels of IRS1, AKT, and GSK3β (Fig. 5H) . These results are consistent with the notion that TRUSS promotes HFD-induced inflammatory response and metabolic disorders.
HepatoCyte-SpeCIFIC tRuSS aBlatIoN alleVIateS geNetIC oBeSIty-aSSoCIateD HepatIC SteatoSIS, IR, aND INFlaMMatIoN
To further access the metabolic regulatory role of TRUSS, we disrupted the expression of TRUSS in the leptin-deficient ob/ob mice (Supporting Fig. S4A ), a commonly used mouse model for type 2 diabetes mellitus and metabolic syndrome. (25) The ob/ob mice with ablation of TRUSS in the hepatocytes are referred to as ob/ob-HKO mice, and the ob/ob-Flox mice refer to GTT (D) and ITT (E) with the corresponding areas under the curve in the TRUSS-Flox and TRUSS-HKO mice after HFD feeding for 11 weeks (n = 16-18 mice/group). Real-time PCR analysis (F) (n = 4 mice/group) and western blot analysis (G) (n = 6 mice/group) for expression of PEPCK and G6Pase in the indicated groups. (H) Representative western blot (top) and quantification (bottom) of the phosphorylation levels of key factors in insulin signaling including IRS1, AKT and GSK3β in the livers from 12 weeks HFD-fed TRUSS-Flox or TRUSS-HKO mice after insulin administration (n = 3 mice/group without insulin injection, n = 6 mice/group with insulin injection). *P < 0.05, comparing the Flox-NC and Flox-HFD groups; # P < 0.05, comparing the Flox-HFD and HKO-HKO groups. Flox indicates the TRUSS-Flox group; HKO indicates the TRUSS-HKO group.
FIg. 4. HFD-induced hepatic steatosis and inflammation are exacerbated by TRUSS-HTG. (A) BW curves for the TRUSS-HTG mice and their control littermates during the 12 weeks of the NC diet or HFD (n = 17-18 mice/group). LW (B) and LW/BW ratios (C) of the WT and TRUSS-HTG mice that were fed with NC diet or HFD for 12 weeks (n = 17-18 mice/group). (D) Serum ALT and AST levels of the mice in the indicated groups (n = 17-18 mice/group). (E) Representative images of H&E (left) and ORO (right)
staining of liver sections from WT and TRUSS-HTG mice that were fed with HFD for 12 weeks (n = 4-5 mice/group; scale bars = 100 μm). (F) Liver TG, TC, and NEFA contents (n = 17-18 mice/group). (G) Serum levels of TG, TC, and NFFA in the indicated groups (n = 17-18 mice/group). (H) Real-time PCR analyses of the mRNA levels of gene-related lipid synthesis (SREBP-1c, FAS, and ACCα) and β-oxidation (CPT-1α, PPARα, and ACOX-1) in the livers of WT and TRUSS-HTG mice that were fed with HFD for 12 weeks (n = 4 mice/group). (I) Serum levels of inflammatory factors IL-1β, IL-6, and TNFα in the livers of WT and TRUSS-HTG mice that were fed with HFD for 12 weeks (n = 18 mice/group). (J) Real-time PCR analyses of the mRNA levels of inflammatory factors IL-1β, IL-6, TNFα, MCP1, and IL-10 in the livers of WT and TRUSS-HTG mice that were fed with HFD for 12 weeks (n = 4 mice/ group). *P < 0.05, comparing the WT-NC and HTG-HFD groups; # P < 0.05, comparing the WT-HFD and HTG-HFD groups. HTG indicates the TRUSS-HTG group. the control groups. As expected, the ob/ob-Flox mice spontaneously developed severe obesity, hepatic steatosis, hyperglycemia, IR, and inflammation with the NC diet (Supporting Fig. S4B-S4L ). TRUSS deletion in the hepatocytes significantly alleviated the pathological phenotypes observed in the ob/ob-Flox mice (C) HOMA-IR indices were calculated in each group (n = 17-18 mice/group). GTT (D) and ITT (E) with the corresponding area under the curve for the WT and TRUSS-HTG mice after the HFD for 11 weeks (n = 18 mice/group). Real-time PCR analyses (F) (n = 4 mice/group) and western blot analyses (G) (n = 6 mice/group) of PEPCK and G6Pase in the WT and TRUSS-HTG mice that were fed with HFD for 12 weeks. (H) Representative western blot (top) and quantification (bottom) of the phosphorylation levels of key factors in insulin signaling including IRS1, AKT and GSK3β in the livers from 12 weeks HFD-fed WT or TRUSS-HTG mice after insulin administration (n = 3 mice/group without insulin injection, n = 6 mice/group with insulin injection). *P < 0.05, comparing the WT-NC and HTG-HFD groups; # P < 0.05, comparing the WT-HFD and HTG-HFD groups. HTG indicates the TRUSS-HTG group. Abbreviation: AUC, area under the curve.
(Supporting Fig. S4B-S4L ), although no significant differences were observed between the BWs of the ob/ob-HKO and ob/ob-Flox mice (Supporting Fig.  S4B ). Together, these data suggest that hepatocytespecific deletion of TRUSS protects against genetic obesity-associated metabolic disorders.
tRuSS pRoMoteS HFD-INDuCeD aCtIVatIoN oF NF-ΚB SIgNalINg
These results clearly highlight the aggravating effects of TRUSS on overnutrition-induced hepatic steatosis, abnormal glucose metabolism, IR, and inflammation responses. A considerable number of studies have underscored an essential role of the NF-κB signaling pathway in metabolic pathologies such as obesity and type 2 diabetes. (26) (27) (28) (29) Our results show that the HFD activated NF-κB signaling both in the TRUSS-Flox (Fig. 6A ) and WT mice (Fig. 6B) , as indicated by the increased phosphorylation levels of IKKβ and p65 and degradation of IκBα (Fig. 6A,6B) . Surprisingly, TRUSS-HKO significantly inhibited, while TRUSS-HTG significantly promoted, the degradation of IκBα and phosphorylation of p65; however, IKKβ activation was not affected by manipulation of TRUSS expression (Fig. 6A,6B ). These phenomena were also observed in PA-treated AdshTRUSS-infected and AdTRUSS-infected primary cultured hepatocytes, further demonstrating that the expression levels of TRUSS are tightly associated with NF-κB signaling (Supporting Fig. S5A,S5B ). To further confirm the effect of TRUSS on IKKβ activation, we performed two-hybrid assays to determine the formation of homo-dimers and hetero-dimers among the IKK members. The cDNA sequences of IKKα, IKKβ, and IKKγ were separately inserted into the pM vector containing the DNA-binding domain and into the pVP16 plasmid containing the activation domain. We found that all possible combinations of these constructs increased the luciferase activities as expected (Supporting Fig. S6) . (30, 31) However, overexpressing TRUSS did not alter the luciferase activities (Supporting Fig. S6 ), suggesting that TRUSS had no effect on IKK complex formation. Therefore, to examine whether degradation of IκBα is also dependent on the ubiquitin-proteasome system as previously reported, (32) HA-tagged TRUSSoverexpressing L02 cells were treated with PA alone or PA plus MG132 (proteasome inhibitor). Our data showed that PA led to more obvious decrease in total protein of IκBα in TRUSS-overexpressing L02 cells than that in control (Supporting Fig. S7A ). However, in the presence of MG132 the total protein expression of IκBα was not altered by PA at different time points when comparisons were made within the same group or between the empty vector and HA-TRUSS groups (Fig.  6C) . Moreover, the expression profiles of phosphorylated IκBα were consistent between the two groups, with obvious phosphorylation of IκBα after 3 hours of PA treatment and a decline thereafter (Fig. 6C) . These results together with the data shown in Fig. 6A,6B and Supporting Fig. S5A,S5B suggest that TRUSS promotes IκBα degradation through a proteasome-dependent way without affecting phosphorylation of IκBα. In addition, PA-induced ubiquitination of IκBα in HEK293T cells was enhanced by overexpressing TRUSS (Fig. 6D) .
Co-immunoprecipitation (Co-IP) and GST precipitation experiments in HEK293T cells overexpressing TRUSS and IκBα demonstrated that TRUSS and IκBα are most likely associated with each other (Fig.  6E,6F ). The endogenous interaction between TRUSS and IκBα was also detected in the mouse liver tissue by Co-IP assays (Fig. 6G) . Furthermore, it appears that two regions of TRUSS (amino acids 1-400 and 601-797) were responsible for the binding of TRUSS to IκBα (Supporting Fig. S7B ). These results suggest that the effect of TRUSS on IκBα degradation might be mediated by the direct intermolecular interaction. IκBα degradation is triggered by direct phosphorylation by the IKK complex at two critical serine residues, Ser32 and Ser36. (32, 33) Because phosphorylation of IKKβ or IκBα (Fig. 6A,6B, Supporting Fig. S5A,S5B) was not affected by the genetic alteration of TRUSS, we asked whether IκBα phosphorylation at Ser32 and Ser36 was indispensable for the positive role of TRUSS on IκBα degradation. The L02 cells were transfected with WT IκBα or the serine double mutant of IκBα (IκBα S32A/S36A ) and then treated with PA to induce IκBα degradation and cycloheximide (CHX) to inhibit protein synthesis. The results showed that transfection of TRUSS promoted degradation of WT IκBα, whereas in IκBα S32A/S36A overexpressing cells the degradation of IκBα in both the vector-transfected and TRUSS-transfected groups was almost abolished (Fig. 6H) . Consistently, ubiquitination of IκBα in both the vector-transfected and TRUSS-transfected cells was decreased by introduction of IκBα S32A/S36A (Fig. 6I) . Collectively, we deduce that TRUSS promotes activation of the NF-κB signaling by enhancing ubiquitination and degradation of IκBα and that these processes are secondary to phosphorylation activation of NF-κB. 
NF-ΚB SIgNalINg IS NeCeSSaRy FoR tRuSS-MeDIateD NaFlD
To further test the hypothesis that the NF-κB activation plays an essential role in mediating HFD-induced NAFLD in TRUSS-HTG mice, a rescue experiment was conducted using hepatocyte-specific TRUSS and IκBα S32A/S36A DTG mice. WT, TRUSS-HTG, IκBα S32A/S36A -HTG, and DTG mice were respectively fed with HFD for 12 weeks. Consistently, HFDinduced IκBα degradation and activation of p65 were significantly increased in TRUSS-HTG mice; however, HFD-induced IκBα degradation and activation of p65 were dramatically blunted in IκBα S32A/S36A -HTG and DTG mice (Supporting Fig. S8A ). Although the BWs were comparable among the different experimental groups (Supporting Fig. S8B ), HFD-induced elevations in the LW/BW and LW were decreased significantly in IκBα S32A/S36A -HTG and DTG mice ( Fig.  7A and Supporting Fig. S8C ). The HFD-induced impairment of liver function (Fig. 7B) , accumulation of lipids both in liver and serum (Fig. 7C, Supporting Fig.  S8D,S8E) , and inflammatory response (Fig. 7D,7E) were significantly reduced by introducing IκBα S32A/S36A mutant to the mice. Moreover, HFD-induced abnormal glucose metabolism and IR were also mitigated in IκBα S32A/S36A -HTG and DTG mice (Fig. 7F-7J ). The expression of IκBα was also significantly decreased in livers of patients with simple steatosis and NASH compared with nonsteatosis controls (Supporting Fig.  S8F ). Taken together, these results suggest that the stimulatory effects of TRUSS on the development and progression of NAFLD is largely dependent on NF-κB signaling.
Discussion
We report that TRUSS plays an essential role in developing HFD-induced NAFLD and its associated complications including lipid accumulation, IR, abnormal glucose metabolism, and inflammatory responses. Hepatocyte-specific TRUSS knockout exerted a protective effect on HFD-induced NAFLD, whereas hepatocyte-specific overexpression of TRUSS exacerbated HFD-induced NAFLD. The HFD challenge leads to an increase in TRUSS expression, which in turn accelerates phosphorylation-initiated ubiquitination and degradation of IκBα.
A chronic low-grade inflammatory state, including elevated levels of cytokines and activation of pro-inflammatory signaling pathways, is widely accepted as a potential link between NAFLD and IR, and is tightly related to the progression to NASH. (3, 34, 35) Data from preclinical animal experiments and clinical studies have shown the increased expression levels of pro-inflammatory mediators, such as TNFα, IL-1β, and MCP1 in individuals with NAFLD. (36, 37) Pro-inflammatory mediator, such as IL-1α, led to IR by inhibiting IRS1 signaling cascade, and IL-1α and IL-6 exerted a synergistic effect on the inhibition of IRS1 signaling. (38) In contrast, both in vitro and in vivo experiments revealed that IL-1β and IL-6 increased hepatic cholesterol accumulation through enhancing the expression of sterol regulatory elementbinding protein 2, low-density lipoprotein receptor, and HMGCoA-r. (39) Not surprisingly, feeding the mice with HFD resulted in the generation of proinflammatory cytokines or chemokines both in the liver and serum and enhanced lipid synthesis and hepatic accumulation, as well as caused IR and abnormal glucose metabolism. However, it appeared that all of these pathological alterations are tightly associated with TRUSS, because TRUSS expression was significantly increased in the livers by HFD challenge in mice and in hepatocytes by PA stimulation. More importantly, an increased expression of TRUSS protein was seen in the human samples of steatosis and NASH. These data are a strong indication that TRUSS plays a critical role in NAFLD. However, the mRNA levels of TRUSS were not altered in liver samples of human and mouse with NAFLD. These phenomena could be due to posttranslational modification, as previously reported that TRUSS protein can be degraded by the S-phase E3 ubiquitin ligase Skp2. (40) We next used gain-of-function or loss-of-function approaches to determine whether HFD-induced inflammatory responses, abnormal glucose metabolism, IR, lipid metabolic disorders, and impaired liver function are mediated by TRUSS. Indeed, hepatocyte-specific overexpression of TRUSS promoted HFD-induced hepatic lipid synthesis and accumulation, and impairment of hepatic insulin-signaling sensitivity. Moreover, TRUSS-HTG augmented HFD-induced liver generation of pro-inflammatory cytokines including IL-1β, IL-6, and TNFα; in contrast, TRUSS-HTG also led to a further decreased expression of anti-inflammatory factor IL-10 in the liver. In comparison, TRUSS deficiency in hepatocyte alleviated all of these pathological alterations. Furthermore, exogenous manipulation of TRUSS expression in primary cultured hepatocytes -HTG, TRUSS-HTG, and DTG mice after HFD feeding for 12 weeks. (B) Serum ALT and AST levels (n = 10 mice/group). (C) Representative images of H&E (top) and ORO (bottom) staining of liver sections in mice from the indicated groups that were fed with HFD for 12 weeks (n = 4-5 mice/group; scale bars = 100 μm). (D) Serum levels of inflammatory factors IL-1β, IL-6, and TNFα in mice from indicated groups that were fed with HFD for 12 weeks (n = 10 mice/group). (E) Real-time PCR analyses of the mRNA levels of inflammatory factors IL-1β, IL-6, TNFα, MCP1, and IL-10 in the livers of mice from the indicated groups that were fed with HFD for 12 weeks (n = 4 mice/group). Measurements of fasting blood glucose (F), fasting serum insulin (G), and the HOMA-IR indices (H) (n = 10 mice/group). (I,J) GTT (I), ITT (J), and calculation of their corresponding areas under the curve (n = 10 mice/group). *P < 0.05 versus the WT group; # P < 0.05 versus the TRUSS-HTG group; n.s. indicates no significance. Abbreviation: AUC, area under the curve. corroborated with the results from animal experiments, in which overexpressing TRUSS enhanced PA-induced accumulation of lipids. Liver functions as a central hub for metabolism of glucose and lipids, as well as a strong producer of inflammatory mediators. The effect of TRUSS on hepatic IR and inflammatory response may further promote the release of inflammatory mediators into circulation. Consistent with this notion, previous studies have demonstrated that the higher serum levels of pro-inflammatory cytokines are closely associated with the development and progression of NAFLD, (41) (42) (43) which are comparable with the findings of current studies in which TRUSS-HTG significantly elevated the serum levels of pro-inflammatory cytokines including IL-1β, IL-6, and TNFα. Nevertheless, these findings together are supportive of the hypothesis that TRUSS expression levels in hepatocytes may play a central role in HFDinduced metabolic disorders.
A number of in vivo and in vitro studies have implicated IKKβ/NF-κB signaling in the development of NAFLD and its associated metabolic disorders. (5, (27) (28) (29) Early studies demonstrated that a variety of pathological stimulation triggers NF-κB signaling and upregulates pro-inflammatory cytokines such as IL-1β, IL-6, and TNFα. (28, 29) The activated NF-κB signaling and the generated pro-inflammatory mediators lead to the impairment of insulin signaling and glucose and lipid metabolism. (23, (27) (28) (29) 38, 39, (44) (45) (46) In an early study, Riches et al. (12) revealed that TRUSS interacts with TNF-R1-signaling proteins including IKK subunits and mediates TNFα-dependent activation of NF-κB. Here, our data show that HFD or PA stimulation lead to activation of IKKβ; however, manipulating the expression of TRUSS in hepatocytes did not affect the dimerization between IKK subunits and phosphorylation of IKKβ. Therefore, we speculated that TRUSS may activate NF-κB by affecting the signaling events downstream of IKKβ, rather than regulating IKK activity under the condition of metabolic stress.
Phosphorylation, ubiquitination, and proteasomemediated degradation of IκBα are pivotal steps for NF-κB activation. (33, 47) Indeed, our data have demonstrated that TRUSS overexpression promotes ubiquitination and degradation of IκBα, without altering phosphorylation of IκBα under the condition of PA treatment. Furthermore, in the IκBα S32A/S36A overexpressing cells, PA-induced ubiquitination and degradation of IκBα is almost abolished. These results suggest that metabolic stress-induced, TRUSS-mediated ubiquitination and degradation of IκBα might be secondary to IκBα phosphorylation. Our Co-IP and GST precipitation assays suggest that the TRUSS may regulate IκBα by a direct interaction with IκBα, and two potential regions of TRUSS (amino acids 1-400 and 601-797) were further identified as binding motif to IκBα. Except for being recognized as a role of scaffolding protein, TRUSS has been identified as the receptor for damage-specific DNA-binding protein 1-Cullin4 E3 ligase complex for selective myelocytomatosis degradation in cancer cells. (17) Furthur investigation should be done to determine whether TRUSS serves as a component of E3 ligase complex for metabolic stress-induced IκBα degradation.
Nevertheless, augmented HFD-induced NAFLD, abnormal glucose metabolism, IR, and inflammatory responses in TRUSS-HTG mice were greatly diminished by crossing these mice with IκBα S32A/S36A mutant mice. Although we could not exclude the role of IκBα S32A/S36A itself in the pathophysiological processes under the condition of HFD-induced NAFLD, our evidence suggests that the positive regulatory effect of TRUSS on development of NAFLD and its associated complications is largely dependent on IκBα-mediated activation of NF-κB signaling.
In summary, we suggest a mechanism in which TRUSS-mediated activation of IκBα/NF-κB signaling contributes to a variety of pathological stimuliinduced NAFLD and its related metabolic disorders. These findings may provide insight into developing preventive and/or treatment approaches for NAFLD.
